SCHEMBL15733474

SCHEMBL15733474

O=C(O)c1cc(S(=O)(=O)Cl)c(Cl)cc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 7/20 0.56
CA2 P00918 7/20 0.56
CA12 O43570 6/20 0.56
CA4 P22748 6/20 0.56
CA6 P23280 6/20 0.56
CA7 P43166 6/20 0.56
CA9 Q16790 6/20 0.56
CA13 Q8N1Q1 6/20 0.56
CA14 Q9ULX7 6/20 0.56
CA5B Q9Y2D0 6/20 0.56
CISD1 Q9NZ45 6/20 0.56
CA3 P07451 5/20 0.56
CA5A P35218 3/20 0.56
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11600104 0.85 CISD1 (0.56) CA1CA2CA12CA4CA6
SCHEMBL11232241 0.85 CISD1 (0.77) CA1CA2CA12CA4CA6
SCHEMBL15881406 0.85 CA1 (0.43) CA1CA2CA12CA4CA6
SCHEMBL4716674 0.85 CA12 (0.70) CA1CA2CA12CA4CA6
SCHEMBL31704157 0.85 CA12 (0.70) CA1CA2CA12CA4CA6
SCHEMBL7974511 0.80 CISD1 (0.50) CA1CA2CA12CA4CA6
SCHEMBL10933704 0.80 ALDH1A1 (0.46) CA1CA2CA12CA4CA6
SCHEMBL3201757 0.80 CISD1 (0.50) CA1CA2CA12CA4CA6
SCHEMBL15881366 0.80 ALDH1A1 (0.46) CA1CA2CA12CA4CA6
SCHEMBL2266623 0.78 CA1 (0.42) CA1CA2CA12CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014082889-A1 NOVEL IMIDAZOLINES AS DUAL INHIBITORS OF MDM2 AND MDMX F. HOFFMANN-LA ROCHE AG (CH) 2014-06-05 WO disclosed
US-20140148443-A1 Novel Imidazolines as dual inhibitors of MDM2 and MDMX HOFFMANN-LA ROCHE INC. (US) 2014-05-29 US disclosed
US-20120251954-A1 LITHOGRAPHIC PRINTING PLATE PRECURSOR AND METHOD OF PREPARING THE SAME FUJIFILM CORPORATION (JP) 2012-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148443-A1 Novel Imidazolines as dual inhibitors of MDM2 and MDMX MDM2, MDM4, TP53 CA1 2914/4885CA2 2012/4885CA12 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.